{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-109998","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2024-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.609255+00:00","generated_at":"2026-05-31T01:14:44.734472+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Revelation Biosciences reports Gemini induces dose-dependent IL-10 increases up to 309-fold in Phase 1","bullets":["Gemini induced statistically significant (p<0.05) dose-dependent IL-10 increases: 27-fold (low), 162-fold (mid), 309-fold (high) vs placebo at 2 hours.","No significant increase in pro-inflammatory IL-1b and TNF-a, confirming TLR4 binding unique to Gemini.","Data consistent with prior preclinical acute kidney injury models; supports potential in preventing AKI after cardiac surgery.","Company plans to initiate Phase 1b study in late 2024.","CEO James Rolke highlighted potential to fine-tune innate immune response and speed healing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-109998","json":"https://secwatch.observer/filing/0000950170-24-109998.json","markdown":"https://secwatch.observer/filing/0000950170-24-109998.md","text":"https://secwatch.observer/filing/0000950170-24-109998.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024109998/0000950170-24-109998-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024109998/revb-20240924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:14:44.734472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}